Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "IPO"

141 News Found

Phase 3 data show Dupixent improves signs and symptoms of prurigo nodularis
Biotech | March 27, 2022

Phase 3 data show Dupixent improves signs and symptoms of prurigo nodularis

There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022


Artificial retinal device mimics human optical illusions: WPI-MANA
Biotech | March 10, 2022

Artificial retinal device mimics human optical illusions: WPI-MANA

The team built a multiple ionic device system, each of which had a lithium cobalt oxide channel arranged on a common lithium phosphorus oxynitride electrolyte


Mandaviya launches ICMR/ DHR policy on biomedical innovation & entrepreneurship
Policy | February 25, 2022

Mandaviya launches ICMR/ DHR policy on biomedical innovation & entrepreneurship

This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country


Bajaj Healthcare launches Magnesium L-Threonate in nutraceutical segment.
News | February 23, 2022

Bajaj Healthcare launches Magnesium L-Threonate in nutraceutical segment.

It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others


Biorchestra announces US$45 million series C fundraising
News | February 23, 2022

Biorchestra announces US$45 million series C fundraising

he financing was significantly oversubscribed with high demand from both existing and new investors.


Vestige launches Pre-Gluco Health capsules for the early prevention of diabetes
Healthcare | February 21, 2022

Vestige launches Pre-Gluco Health capsules for the early prevention of diabetes

According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic


Ligand posts strong 2021 performance
News | February 18, 2022

Ligand posts strong 2021 performance

Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.


Kato wins USFDA approval for studies in retinal disorder
Biotech | February 17, 2022

Kato wins USFDA approval for studies in retinal disorder

Resolv ER may remedy leading causes of blindness in adults


We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed
interviews | February 09, 2022

We expect to turn profitable in two years: M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed

MedleyMed is present across the pharma and healthcare value chain. It offers digital solutions to all stake holders and is in the process of expanding its operations in India and USA. In an interview with Thomas C Thottathil, M Satyendra (Satish), Managing Director, Athena Global Technologies & MedleyMed discussed his plans and opportunities in India


EdiGene and Neukio collaborate to develop next-generation immune cell therapies
Biotech | February 09, 2022

EdiGene and Neukio collaborate to develop next-generation immune cell therapies

The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)